Is Buying Jounce Therapeutics Inc (NASDAQ:JNCE) Here Good Idea?

The stock of Jounce Therapeutics Inc (NASDAQ:JNCE) registered an increase of 2.12% in short interest. JNCE’s total short interest was 456,900 shares in September as published by FINRA. Its up 2.12% from 447,400 shares, reported previously. With 125,600 shares average volume, it will take short sellers 4 days to cover their JNCE’s short positions. The short interest to Jounce Therapeutics Inc’s float is 3.15%.

The stock decreased 1.40% or $0.05 during the last trading session, reaching $3.52. About 94,342 shares traded. Jounce Therapeutics, Inc. (NASDAQ:JNCE) has declined 32.15% since September 13, 2018 and is downtrending. It has underperformed by 32.15% the S&P500.

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, focuses on developing therapies that enable the immune system to attack tumors. The company has market cap of $116.10 million. The Company’s lead product candidate, JTX-2011, is a clinical stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in various solid tumors. It currently has negative earnings. The firm is also developing JTX-4014, an anti-PD-1 antibody.

More notable recent Jounce Therapeutics, Inc. (NASDAQ:JNCE) news were published by: Globenewswire.com which released: “Jounce Therapeutics Reports Third Quarter 2018 Financial Results – GlobeNewswire” on November 13, 2018, also Globenewswire.com with their article: “Jounce Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference – GlobeNewswire” published on March 04, 2019, Seekingalpha.com published: “Jounce Therapeutics, Inc. (JNCE) CEO Dr. Rich Murray on Q1 2019 Results – Earnings Call Transcript – Seeking Alpha” on May 09, 2019. More interesting news about Jounce Therapeutics, Inc. (NASDAQ:JNCE) were released by: Seekingalpha.com and their article: “Jounce up 8% on new vopratelimab data – Seeking Alpha” published on April 02, 2019 as well as Globenewswire.com‘s news article titled: “Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation – GlobeNewswire” with publication date: July 23, 2019.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.